8-K: AnaptysBio Reports Strong Six-Month Rosnilimab Data in Rheumatoid Arthritis, Demonstrating Best-in-Disease Profile and JAK-Like Efficacy

AnaptysBio announced positive six-month data from its Phase 2b RENOIR clinical trial for rosnilimab in rheumatoid arthritis, showcasing a best-in-disease profile with JAK-like efficacy and a favorable safety profile.

Summary

• AnaptysBio's investigational rosnilimab, a PD-1+ T cell depleter and agonist, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA) in the robust, global 424-patient Phase 2b RENOIR trial.
• Rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period.
• Responses were durable for at least two months off drug, suggesting potential for extended dosing intervals (e.g., Q8W) in the maintenance setting.
• The drug was safe and well tolerated, particularly when compared to standard of care biologics or JAKs, with no treatment-related serious adverse events (SAEs), malignancies, anaphylaxis, or systemic hypersensitivity.
• At Week 14, 69% (220 of 318) of rosnilimab patients in the intent-to-treat (ITT) population achieved CDAI LDA, increasing to 73% (232 of 318) if additional patients trending towards LDA were included.
• For b/tsDMARD-naive patients at Week 28, CDAI LDA ranged from 53% to 72%, ACR50 from 52% to 69%, and ACR70 from 37% to 55% across different doses.
• For b/tsDMARD-experienced patients at Week 28, CDAI LDA ranged from 34% to 56%, ACR50 from 27% to 44%, and ACR70 from 23% to 36% across different doses.
• Patient-reported outcomes showed significant improvements, with Pain VAS improving by approximately 50 points (from ~65 to ~15) and HAQ-DI reducing by 0.9 points (from ~1.6 to ~0.7).
• Translational data confirmed on-target pharmacological activity, including a ~50% reduction in mean C-reactive protein (CRP) and ~90% reduction in PD-1+ T cells in synovial biopsies at higher doses.
• The company reported a strong capital position with approximately $383 million in cash as of Q1 2025, providing an expected cash runway through year-end 2027.
• AnaptysBio is assessing strategic paths for rosnilimab, including securing a global partnership for Phase 3 development in RA and UC, or independently advancing UC into Phase 3.
• The company's pipeline also includes ANB033 (CD122 antagonist) and ANB101 (BDCA2 modulator) in Phase 1 trials, with initial data for rosnilimab in ulcerative colitis expected in Q4 2025.

Sentiment

Score: 9

Explanation: The document reports highly positive clinical trial results for rosnilimab in rheumatoid arthritis, demonstrating strong efficacy comparable to or exceeding current standards of care, coupled with a superior safety profile. The durability of response and potential for extended dosing intervals are significant advantages. The company also highlights a strong financial position and clear strategic next steps, indicating a very positive outlook for the lead asset and the company's overall pipeline.

Positives

• Rosnilimab demonstrated a 'best-in-disease profile' in moderate-to-severe RA, achieving JAK-like efficacy on multiple clinically meaningful measures.
• The drug showed durable responses for at least two months off drug, suggesting potential for extended dosing intervals (e.g., Q8W) in maintenance treatment.
• Rosnilimab exhibited a favorable safety and tolerability profile across all doses, with no treatment-related serious adverse events (SAEs), malignancies, anaphylaxis, or systemic hypersensitivity.
• Less than 2% of patients discontinued rosnilimab due to an adverse event throughout the entire trial.
• Significant improvements were observed in patient-reported outcomes, including a ~50-point reduction in Pain Visual Analog Scale (VAS) and a 0.9-point reduction in HAQ-Disability Index (DI).
• Objective translational data, such as a ~50% reduction in CRP and ~90% reduction in PD-1+ T cells in synovial biopsies, substantiated the clinical outcomes.
• The company has a strong capital position with approximately $383 million in cash as of Q1 2025, providing an expected cash runway through year-end 2027.
• AnaptysBio has potential for significant royalty and milestone payments from its collaborations with GSK (Jemperli, cobolimab) and Vanda Pharmaceuticals (imsidolimab).

Negatives

• Max response rates for rosnilimab have not yet been observed due to strict continuation criteria at Week 14, which prevented patients with meaningful improvement from continuing treatment in the trial.
• The 100mg Q4W dose for b/tsDMARD-experienced patients showed a decrease in CDAI LDA from Week 12 to Week 28 (-9%), and a decrease in ACR50 (-12%).
• While overall safety was favorable, the incidence rate of 'Any AE' (per 100 PY) for rosnilimab doses (149.1 to 260.9) was higher than placebo (125.6) over the Week 0-28 period.
• The incidence rate of 'Any SAE' (per 100 PY) for rosnilimab doses (3.7 to 7.7) was higher than placebo (2.4) over the Week 0-28 period, although no drug-related SAEs were reported for rosnilimab.

Risks

• The company's ability to advance its product candidates, obtain regulatory approval, and ultimately commercialize them is subject to risks and uncertainties.
• The timing and results of preclinical and clinical trials may differ from expectations.
• The company's ability to fund development activities and achieve development goals is a risk factor.
• Protecting intellectual property is crucial and subject to risks.
• The strict continuation criteria in the Phase 2b trial may have capped the observed maximum response rates, potentially understating rosnilimab's full efficacy profile.

Future Outlook

AnaptysBio plans to present the full RA Phase 2b data at a future medical congress. The company is evaluating two strategic paths for rosnilimab: securing a global partnership to advance the drug into Phase 3 for both RA and UC, or independently advancing rosnilimab in UC into Phase 3, assuming positive Phase 2 data. Initial data for the Phase 2 UC trial is expected in Q4 2025. Beyond 2026, the company aims for Phase 3 enablement activities, including drug supply scale-up and regulatory interactions, and initiating Phase 2 studies in additional indications.

Management Comments

• Daniel Faga, President and CEO of Anaptys, stated: 'This is exciting news for patients living with RA, who cycle through numerous treatment options without achieving a low level of disease activity shown to be correlated with slowing of disease progression. The updated Phase 2b data for rosnilimab confirm a best-in-disease profile through six months that is safe and well tolerated, with JAK-like efficacy and the potential to be administered in a monthly, subcutaneous dose. Additionally, responses after six months of treatment are durable for at least two months off drug, suggesting the potential for extended, every eight-week dosing intervals during maintenance treatment.'
• Daniel Faga also commented: 'These findings, consistent with compelling and objective translational data, surpass our target product profile for rosnilimab in the ~$20 billion U.S. RA market. Our next priority is to complete the ongoing Phase 2 study for rosnilimab in UC, which is on track to report initial data in Q4 2025.'
• Jonathan Graf, M.D., Professor of Medicine, Division of Rheumatology at UCSF and RENOIR investigator, remarked: 'Witnessing rosnilimab, with its novel mode of action, dramatically reduce RA disease activity through six months in most patients, whether having failed multiple classes of b/tsDMARD therapies or b/tsDMARD-naive, is truly exciting for patients living with this disease and the field of RA treatment.'
• Paul Emery, M.D., Professor of Rheumatology at the University of Leeds, stated: 'To date, rosnilimab has shown a safe and well tolerated profile with almost all patients choosing to stay on therapy through the end of the study. Rosnilimab has not demonstrated any concerning safety trends or signals, such as those seen with the JAK inhibitors and most other biologics. This is remarkable, given these patients have a two-to-threefold increased risk of comorbidities such as infections, cardiac events and malignancies, before accounting for the impact of background DMARDs, mostly methotrexate.'
• Paul Lizzul, M.D., Ph.D., MPH, MBA, Chief Medical Officer of Anaptys, commented: 'Beyond achieving necessary symptomatic improvements and reductions, we strive to advance treatment toward the clinical resolution of disease by restoring immune homeostasis. Today’s updated positive data reinforce our targeted goals with the added potential for convenient monthly dosing through six months and beyond, on top of maintaining sustainable and durable outcomes.'

Industry Context

The announcement positions rosnilimab as a potentially significant new mechanism of action (MoA) in the ~$20 billion U.S. rheumatoid arthritis market, which has not seen a new MoA approved since 2012. Its 'best-in-disease profile' and JAK-like efficacy, coupled with a favorable safety profile, suggest it could address the substantial unmet need for safe, effective, and durable therapies, particularly for patients who cycle through existing treatment options. The potential for monthly or even every eight-week subcutaneous dosing could offer a significant convenience advantage over current standard-of-care biologics and JAK inhibitors, which often carry black box warnings for serious adverse events.

Comparison to Industry Standards

• Rosnilimab demonstrated 'JAK-like efficacy' on multiple clinically meaningful measures, including CDAI LDA, CDAI remission, and ACR70 response, over a six-month period.
• In b/tsDMARD-naive patients, rosnilimab (pooled doses) showed higher CDAI LDA (64%) at Week 28 compared to Rinvoq (60% at Week 24/26), Humira (48% at Week 28), and Kevzara (53% at Week 24/26) in their respective Phase 3 studies (SELECT-COMPARE, MONARCH).
• For ACR50 in b/tsDMARD-naive patients, rosnilimab (pooled doses) achieved 53% at Week 28, comparable to Humira (54% at Week 28) and higher than Kevzara (35% at Week 24/26).
• For ACR70 in b/tsDMARD-naive patients, rosnilimab (pooled doses) achieved 42% at Week 28, comparable to Humira (46% at Week 28) and higher than Kevzara (23% at Week 24/26).
• In b/tsDMARD-experienced patients, rosnilimab's mid/high doses (400mg Q4W and 600mg Q2W) showed CDAI LDA rates of 56% and 49% respectively at Week 28, comparable to Rinvoq (58% at Week 24) and Orencia (59% at Week 24) in their H2H SELECT-CHOICE Phase 3 studies.
• Rosnilimab's ACR20 response rates at Week 12 in b/tsDMARD-experienced patients (59-68% across doses) were comparable to Rinvoq's Phase 2b TNF-experienced study (58%).
• CRP reductions at Week 12 for rosnilimab in b/tsDMARD-experienced patients were comparable to Rinvoq's Phase 2b TNF-experienced study.
• Rosnilimab's safety profile was described as 'favorable' and 'well tolerated,' particularly when compared to standard of care biologics or JAKs, which often carry black box warnings for increased risks of infections, MACE, and malignancies.
• Rosnilimab demonstrated greater and more durable depletion of PD-1high T cells compared to Lilly's peresolimab, with rosnilimab showing greater depletion even 12-14 weeks off-drug, while peresolimab's maximum was 57% on-drug.

Stakeholder Impact

• **Shareholders/Investors**: Positive clinical data and a strong cash position are likely to increase investor confidence and potentially lead to share price appreciation. The strategic decision regarding partnership vs. independent development will be key for future value.
• **Patients with Rheumatoid Arthritis**: Rosnilimab offers a promising new treatment option with a novel mechanism of action, JAK-like efficacy, and a favorable safety profile, potentially leading to better disease control and quality of life, especially for those who have failed previous therapies.
• **Healthcare Providers**: The drug's efficacy, safety, and potential for convenient monthly or extended dosing could make it an attractive option for managing RA patients.
• **Competitors**: The strong data for rosnilimab could increase competitive pressure on companies marketing existing RA treatments, particularly JAK inhibitors and biologics with less favorable safety profiles.

Next Steps

• Present full RA Phase 2b data at a future medical congress.
• Assess two alternative strategic paths for rosnilimab: securing a global partnership to advance in all indications (RA and UC Phase 3) or independently advancing UC into Phase 3 (assuming Phase 2 data meets TPP).
• Complete the ongoing Phase 2 study for rosnilimab in ulcerative colitis, with initial data expected in Q4 2025.
• Initiate Phase 3 enablement activities for rosnilimab in 2026+, including drug supply scale-up and regulatory interactions.
• Initiate Phase 2 studies for rosnilimab in additional indications in 2026+.
• Conduct an R&D event for ANB033 (CD122 antagonist) in H2 2025.

Key Dates

Recommendation

Keywords

Rosnilimab, Rheumatoid Arthritis, RA, Phase 2b, Clinical Trial, Biotechnology, Immunology, PD-1, T cells, Autoimmune Disease, AnaptysBio, RENOIR, JAK-like efficacy, CDAI, ACR70, Biologics, JAK inhibitors, Ulcerative Colitis, ANB033, ANB101, Drug Development